Skip to main content

Autolus Therapeutics plc

AUTL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001730463

In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Autolus Therapeutics plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $15.7K in total
Insiders trading
1
Net value
−$15.7K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Autolus Therapeutics plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Autolus Therapeutics plc
NameTitleLast reported holdingLast filingFilings, past year
Piccina CintiaU.S. CCO & Country Gen Manager13,287Sep 3, 20261
Young William DDirector–Jul 1, 20261
Rao Madduri RavinDirector–Jul 1, 20261
Richardson RyanDirector–Jul 1, 20261
Leiderman ElisabethDirector–Jul 1, 20261
Iannone RobertDirector–Jul 1, 20261
Butitta Cynthia MDirector–Jul 1, 20261
Bain LindaDirector–Jul 1, 20261
Azelby RobertDirector–Jul 1, 20261
Bonney Michael WDirector–Jul 1, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 3, 2026 (view filing)4:36 PM ETSep 21 dayPiccina CintiaU.S. CCO & Country Gen ManagerSSaleAmerican Depositary Shares−6.71K$2.34−$15.7K−33.6%13.3K after